The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...
Artificial intelligence could be used to prescribe medications to patients — if a new bill makes its way through Congress ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback